Quick Answer
ANI PHARMACEUTICALS INC reported Stockholders Equity of $540.72 million for the year ending 2025.
- ANI PHARMACEUTICALS INC showed an increase of +33.9% in Stockholders Equity from 2024 to 2025.
- This data is from ANI PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $44.15 million | Q1 2012: $38.00 million | Q2 2012: $30.92 million | Q3 2012: $32.29 million | Q1 2013: $26.03 million | Q2 2013: $35.49 million | Q3 2013: $36.69 million | Q1 2014: $92.09 million | Q2 2014: $91.60 million | Q3 2014: $99.49 million | Q1 2015: $144.74 million | Q2 2015: $149.50 million | Q3 2015: $155.89 million | Q1 2016: $160.18 million | Q2 2016: $163.78 million | Q3 2016: $168.83 million | Q1 2017: $172.21 million | Q2 2017: $176.55 million | Q3 2017: $182.80 million | Q1 2018: $179.64 million | Q2 2018: $185.11 million | Q3 2018: $192.47 million | Q1 2019: $199.71 million | Q2 2019: $207.66 million | Q3 2019: $213.13 million | Q1 2020: $201.17 million | Q2 2020: $191.34 million | Q3 2020: $195.10 million | Q4 2020: $195.70 million | Q1 2021: $203.71 million | Q2 2021: $191.92 million | Q3 2021: $191.40 million | Q1 2022: $321.24 million | Q2 2022: $312.11 million | Q3 2022: $311.83 million | Q1 2023: $314.63 million | Q2 2023: $409.62 million | Q3 2023: $429.86 million | Q1 2024: $451.96 million | Q2 2024: $455.76 million | Q3 2024: $405.95 million | Q1 2025: $418.62 million | Q2 2025: $436.76 million | Q3 2025: $505.82 million.
- Over the full 18 years of available data (2008 to 2025), ANI PHARMACEUTICALS INC's Stockholders Equity has grown by 3,810.8%.
- Historical annual values: Fiscal year 2025: $540.72 million | Fiscal year 2024: $403.68 million | Fiscal year 2023: $432.75 million | Fiscal year 2022: $313.69 million | Fiscal year 2021: $333.89 million | Fiscal year 2020: $195.70 million | Fiscal year 2019: $212.79 million | Fiscal year 2018: $197.26 million | Fiscal year 2017: $174.76 million | Fiscal year 2016: $169.65 million | Fiscal year 2015: $160.08 million | Fiscal year 2014: $139.79 million | Fiscal year 2013: $40.96 million | Fiscal year 2012: -$42.72 million | Fiscal year 2011: -$34.28 million | Fiscal year 2010: $19.15 million | Fiscal year 2009: $15.83 million | Fiscal year 2008: $13.83 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: